The Effect of a High-dose Oral Vitamin D3 Bolus on Serum 25(OH)D3 and Vitamin D Receptor Target Gene Expression (VitDbol)
Vitamin D Receptor Target Gene Expression
Serum 25(OH)D Concentration
Dietary Supplement: Vitamin D3
|Study Design:||Allocation: Randomized
Endpoint Classification: Pharmacokinetics/Dynamics Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Basic Science
|Official Title:||The Effect of a High-dose Oral Vitamin D3 Bolus on Serum 25-hydroxyvitamin D3 and Vitamin D Receptor Target Gene Expression (VitDbol)|
- Change from baseline in vitamin D target gene expression [ Time Frame: 24 h, 48 h, and 30 days after the baseline ] [ Designated as safety issue: No ]Effect of 2000 microgram vitamin D3 dose or placebo on the expression of vitamin D receptor target genes
- Change from baseline in serum 25(OH)D [ Time Frame: 24 h, 48 h, and 30 days after the baseline ] [ Designated as safety issue: Yes ]Effect of 2000 microgram vitamin D3 dose or placebo on serum 25(OH)D3 concentrations
- Change from baseline in immunomarkers [ Time Frame: 24 h, 48 h, and 30 days after the baseline ] [ Designated as safety issue: Yes ]Effect of 2000 microgram Vitamin D3 dose or placebo on immune system and inflammatory responses, such as hs-CRP, IL-6, TNF-alfa and IL-1RA.
- Change from baseline in glucose metabolism [ Time Frame: 24 h, 48 h, and 30 days after the baseline ] [ Designated as safety issue: Yes ]Effect of 2000 microgram vitamin D3 dose or placebo on glucose metabolism responses, i.e. blood glucose and insulin
- Change from baseline in safety measurements [ Time Frame: 48 h and 30 days after the baseline ] [ Designated as safety issue: Yes ]Serum calcium, alanine transaminase (ALAT), gamma-glutamyl transferase (GGT) and creatinine
|Study Start Date:||February 2014|
|Estimated Study Completion Date:||June 2015|
|Estimated Primary Completion Date:||June 2015 (Final data collection date for primary outcome measure)|
Active Comparator: Vitamin D3
2000 micrograms of vitamin D3 in two doses during one day
Dietary Supplement: Vitamin D3
In total 25 pills will be taken by the subjects, each containing 80 micrograms of vitamin D3 or placebo. Of the 25 pills, 13 will be taken in the morning with breakfast and 12 with lunch.
Other Name: cholecalciferol
Placebo Comparator: Placebo
Placebo in two doses during one day
Serum 25-hydroxyvitamin D [25(OH)D3] is a well-established marker for vitamin D status of the human body. In addition to the general importance of vitamin D for bone health, low serum 25(OH)D3 concentrations have been associated with increased risk of several health outcomes, such as autoimmune diseases, type 2 diabetes and cardiovascular complications. However, there is significant inter-individual variation in the average serum 25(OH)D3 concentrations and also in the response to supplementation with vitamin D. Genetic and epigenetic factors have been suggested to be responsible for a large part of the variation, but currently there is little information about the health effects of the variation.
In our previous study (VitDmet, Clinicaltrials.gov NCT01479933) we showed that only half of the participants responded to the 5-month vitamin D3 supplementation of 40 µg/day or 80 µg/day as expected and that certain vitamin D receptor (VDR) target genes were suitable biomarkers for displaying the transcriptomic response of human tissues to vitamin D3 supplementation.
The purpose of the current study is to investigate whether a high-dose vitamin D3 oral bolus produces marked VDR target gene expression response and whether there is large inter-individual variation, as what was suggested with the 5-month lower-dose supplementation.
In the Trial 1, the subjects are randomized to receive either 2,000 micrograms (80 000 IU) of vitamin D3 (n=20) or placebo (n=10) in one day. Blood samples are collected for peripheral blood mononuclear cell isolation and serum 25(OH)D3 measurements at baseline and 24 h and 48 h and 30 days after the first dose. Blood samples are also collected for immunomarker analyses. In the Trial 2, the procedures of the Trial 1 are repeated in two subjects with known low and high serum 25(OH)D3 concentrations in order to investigate more specifically the impact of different starting levels of serum 25(OH)D3.
In February 2015, new subjects have been recruited to enter the Trial 1 in order to increase the size of the study. All the new subjects will receive the 2,000 microgram bolus of vitamin D3, there will be now new subjects in the placebo arm.
Please refer to this study by its ClinicalTrials.gov identifier: NCT02063334
|Contact: Jyrki K Virtanen, PhDfirstname.lastname@example.org|
|Contact: Tomi-Pekka Tuomainen, MD, PhDemail@example.com|
|University of Eastern Finland||Recruiting|
|Kuopio, Finland, 70211|
|Contact: Jyrki K Virtanen, PhD +358294454542 firstname.lastname@example.org|
|Contact: Tomi-Pekka Tuomainen, MD, PhD +358-294454533 email@example.com|
|Principal Investigator: Jyrki K Virtanen, PhD|
|Sub-Investigator: Tomi-Pekka Tuomainen, MD, PhD|
|Sub-Investigator: Jaakko Mursu, PhD|
|Sub-Investigator: Sari Voutilainen, PhD|
|Sub-Investigator: Tarja Nurmi, PhD|
|Sub-Investigator: Matti Uusitupa, MD, PhD|
|Sub-Investigator: Jussi Pihlajamäki, MD, PhD|
|Sub-Investigator: Carsten Carlberg, PhD|
|Principal Investigator:||Jyrki K Virtanen, PhD||University of Eastern Finland|